Sanaria, Inc.

Publicly observed

Rockville, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Rockville	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Sanaria, Inc.	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	YLF2SS2NYGC5	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant18 Sept 2026Publicly observed
NIH SBIR/STTR award: New cryovials with integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products.
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant14 Apr 2023Publicly observed
NIH SBIR/STTR award: Progressing PfSPZ vaccines for malaria to licensure and commercialization
USD 995,072.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant21 Apr 2020Publicly observed
NIH SBIR/STTR award: A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage
USD 999,150.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant21 Apr 2016Publicly observed
NIH SBIR/STTR award: Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant21 Apr 2016Publicly observed
NIH SBIR/STTR award: Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.